Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 5/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | RECQL | P46063 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HMGCR | P04035 | 3/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | CDC25A | P30304 | 5/20 | 0.33 |
| ▸ | CDC25B | P30305 | 5/20 | 0.33 |
| ▸ | CDC25C | P30307 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15518629 | 0.89 | TDP1 (0.40) | PTPN7TDP1RECQLMAPTKDM4E | |
| SCHEMBL15520246 | 0.84 | TDP1 (0.42) | PTPN7TDP1RECQLMAPTKDM4E | |
| SCHEMBL15517158 | 0.84 | TDP1 (0.39) | PTPN7TDP1RECQLMAPTKDM4E | |
| SCHEMBL15518487 | 0.84 | TDP1 (0.45) | PTPN7TDP1RECQLMAPTKDM4E | |
| SCHEMBL7320816 | 0.81 | F13A1 (0.47) | TDP1MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL7320019 | 0.81 | F13A1 (0.47) | TDP1MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL16067271 | 0.81 | ALOX15 (0.41) | TDP1MAPTALDH1A1SMN1; SMN2CDC25A | |
| SCHEMBL15518472 | 0.79 | PTPN2 (0.33) | TDP1MAPTALDH1A1CDC25BLMNA | |
| SCHEMBL11101641 | 0.79 | MAPT (0.49) | TDP1MAPTALDH1A1CDC25BLMNA | |
| SCHEMBL11093696 | 0.79 | MAPT (0.53) | TDP1MAPTALDH1A1CDC25BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170209393-A1 | BENZOQUINONE DERIVATIVES FOR TREATING OXIDATIVE STRESS DISORDERS | BIOELECTRON TECHNOLOGY CORPORATION | 2017-07-27 | — | — | US | claimed |
| US-9629815-B2 | Benzoquinone derivatives for treating oxidative stress disorders | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2017-04-25 | — | — | US | claimed |
| US-20150218079-A1 | BENZOQUINONE DERIVATIVES FOR TREATING OXIDATIVE STRESS DISORDERS | EDISON PHARMACEUTICALS, INC. (US) | 2015-08-06 | — | — | US | claimed |
| US-20170209393-A1 | BENZOQUINONE DERIVATIVES FOR TREATING OXIDATIVE STRESS DISORDERS | BIOELECTRON TECHNOLOGY CORPORATION | 2017-07-27 | — | — | US | disclosed |
| US-9629815-B2 | Benzoquinone derivatives for treating oxidative stress disorders | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2017-04-25 | — | — | US | disclosed |
| US-20150216820-A1 | QUINONE DERIVATIVES FOR USE IN THE MODULATION OF REDOX STATUS OF INDIVIDUALS | BIOELECTRON TECHNOLOGY CORPORATION | 2015-08-06 | — | — | US | disclosed |
| US-20150218079-A1 | BENZOQUINONE DERIVATIVES FOR TREATING OXIDATIVE STRESS DISORDERS | EDISON PHARMACEUTICALS, INC. (US) | 2015-08-06 | — | — | US | disclosed |
| EP-2892515-A1 | BENZOQUINONE DERIVATIVES FOR TREATING OXIDATIVE STRESS DISORDERS | Edison Pharmaceuticals, Inc. (US) | 2015-07-15 | — | — | EP | disclosed |
| EP-2892516-A1 | QUINONE DERIVATIVES FOR USE IN THE MODULATION OF REDOX STATUS OF INDIVIDUALS | Edison Pharmaceuticals, Inc. (US) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014039862-A1 | QUINONE DERIVATIVES FOR USE IN THE MODULATION OF REDOX STATUS OF INDIVIDUALS | EDISON PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | WO | disclosed |
| WO-2014039917-A1 | BENZOQUINONE DERIVATIVES FOR TREATING OXIDATIVE STRESS DISORDERS | EDISON PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170209393-A1 | BENZOQUINONE DERIVATIVES FOR TREATING OXIDATIVE STRESS DISORDERS | UQCRC1, TXN2, CYC1 | PTPN7 4444/4885TDP1 778/4885RECQL 177/4885 |
| US-20150218079-A1 | BENZOQUINONE DERIVATIVES FOR TREATING OXIDATIVE STRESS DISORDERS | UQCRC1, CYC1, UQCRC2 | PTPN7 4553/4885TDP1 686/4885RECQL 177/4885 |
| US-20150216820-A1 | QUINONE DERIVATIVES FOR USE IN THE MODULATION OF REDOX STATUS OF INDIVIDUALS | GSR, GLS, GPX4 | PTPN7 1378/4885TDP1 1828/4885RECQL 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.